Setmelanotide vs Pemvidutide
Head-to-head comparison of Setmelanotide (Setmelanotide Acetate) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Setmelanotide | Pemvidutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Setmelanotide Acetate | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 11-16 hours | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | 1-3 mg daily | Trial-dependent; once-weekly SC titration |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 18 |
| Research Status | Clinical | Clinical |
Setmelanotide Benefits
- ✓reduced hyperphagia
- ✓body-weight reduction
- ✓MC4R pathway activation
- ✓improved satiety signaling
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Setmelanotide Dosing
1 mg SC daily|titrate weekly to 2-3 mg/day|follow study or label-based escalation
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Setmelanotide Side Effects
- ⚠hyperpigmentation
- ⚠nausea
- ⚠injection-site reactions
- ⚠fatigue
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Setmelanotide
Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.